Search Results - "VERSCHRAEGEN, C"

Breast-conserving surgery with or without radiotherapy: Pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality by VINH-HUNG, Vincent, VERSCHRAEGEN, Claire

“…The objective of the study was to investigate whether radiotherapy or its omission after breast-conserving surgery has measurable consequences on local tumor…”
Get full text

Epidermal growth factor receptor as a biomarker for cervical cancer by Soonthornthum, T., Arias-Pulido, H., Joste, N., Lomo, L., Muller, C., Rutledge, T., Verschraegen, C.

“…This review focuses on the different modes of expression of the epidermal growth factor receptor (EGFR). All methods used to assess EGFR expression are…”
Get full text

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study by O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., Verschraegen, C., Humphrey, R., Ibrahim, R., de Pril, V., Hoos, A., Wolchok, J.D.

“…This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced…”
Get full text

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer by Verschraegen, C.F., Czok, S., Muller, C.Y., Boyd, L., Lee, S.J., Rutledge, T., Blank, S., Pothuri, B., Eberhardt, S., Muggia, F.

“…Suppression of neoangiogenesis and pegylated liposomal doxorubicin (PLD) each contribute to the management of platinum-resistant/refractory ovarian cancer. The…”
Get full text

Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer by Ades, S., Kumar, S., Alam, M., Goodwin, A., Weckstein, D., Dugan, M., Ashikaga, T., Evans, M., Verschraegen, C., Holmes, C. E.

“…Summary Background Patients with metastatic colon cancer (mCRC) are at increased risk of venous thromboembolism (VTE). Limited preclinical data suggest that…”
Get full text

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen by Verschraegen, C.F., Arias-Pulido, H., Lee, S.-J., Movva, S., Cerilli, L.A., Eberhardt, S., Schmit, B., Quinn, R., Muller, C.Y., Rabinowitz, I., Purdy, M., Snyder, D., Bocklage, T.

“…To assess the response of patients with soft tissue sarcoma (STS) to the combination of docetaxel, bevacizumab, and gemcitabine. Vascular endothelial growth…”
Get full text

Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim by Moukharskaya, J., Abrams, D. M., Ashikaga, T., Khan, F., Schwartz, J., Wilson, K., Verschraegen, C., Openshaw, T., Valentine, J., Eneman, J., Unger, P., Ades, S.

“…Purpose Bone pain is a common side effect of pegfilgrastim and can interfere with quality of life and treatment adherence. This study investigated the impact…”
Get full text

Immune related adverse events across cancer types: Incidence, risk factors and survival by Owen, D.H., Burkart, J., Patel, S., Wei, L., Tinoco, G., Liebner, D., He, K., Shields, P.G., Bertino, E.M., Presley, C.J., Johns, A., Folefac, E., Olencki, T., Carbone, D.P., Verschraegen, C., Otterson, G.A., Kendra, K.L.

Get full text

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference by Hassan, R, Alexander, R, Antman, K, Boffetta, P, Churg, A, Coit, D, Hausner, P, Kennedy, R, Kindler, H, Metintas, M, Mutti, L, Onda, M, Pass, H, Premkumar, A, Roggli, V, Sterman, D, Sugarbaker, P, Taub, R, Verschraegen, C

“…Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site…”
Get full text

GnRH antagonists in the treatment of gynecological and breast cancers by Emons, G, Gründker, C, Günthert, A R, Westphalen, S, Kavanagh, J, Verschraegen, C

“…Approximately 80% of human ovarian and endometrial cancers and 50% of breast cancers express GnRH and its receptor as part of an autocrine regulatory system…”
Get full text

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer by McMeekin, S, Patel, R, Verschraegen, C, Celano, P, Burke, J, Plaxe, S, Ghatage, P, Giurescu, M, Stredder, C, Wang, Y, Schmelter, T

“…Background: Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II,…”
Get full text

Recombinant human thrombopoietin attenuates carboplatin-induced severe Thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer by VADHAN-RAJ, S, VERSCHRAEGEN, C. F, KAVANAGH, J. J, BUESO-RAMOS, C, BROXMEYER, H. E, KUDELKA, A. P, FREEDMAN, R. S, EDWARDS, C. L, GERSHENSON, D, JONES, D, ASHBY, M

“…Thrombocytopenia is a significant problem in the treatment of cancer. To assess the clinical safety of therapy with recombinant human thrombopoietin (rhTPO)…”
Get full text

Absence of epidermal growth factor receptor mutations in cervical cancer by Arias-Pulido, H, Joste, N, Chavez, A, Muller, C Y, Dai, D, Smith, H O, Verschraegen, C F

“…Epidermal growth factor receptor (EGFR) is overexpressed in the majority of cervical cancers (CCs). Somatic mutations of EGFR have been associated with…”
Get more information

Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470 by Kudelka, Andrzej P, Verschraegen, Claire F, Loyer, Evelyn

“…To the Editor: TNP-470 is a new inhibitor of angiogenesis that has shown potent antitumor activity in preclinical studies. 1 – 4 We performed a phase 1 study…”
Get full text

Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma by Verschraegen, C F, Sittisomwong, T, Kudelka, A P, Guedes, E d, Steger, M, Nelson-Taylor, T, Vincent, M, Rogers, R, Atkinson, E N, Kavanagh, J J

“…To determine the efficacy and toxicity of docetaxel in patients with müllerian carcinoma resistant to paclitaxel. Thirty-two patients with epithelial ovarian…”
Get full text

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix by Verschraegen, C F, Levy, T, Kudelka, A P, Llerena, E, Ende, K, Freedman, R S, Edwards, C L, Hord, M, Steger, M, Kaplan, A L, Kieback, D, Fishman, A, Kavanagh, J J

“…A phase II study was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11), a water-soluble derivative of camptothecin, in patients…”
Get more information

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma by Kudelka, A P, Tresukosol, D, Edwards, C L, Freedman, R S, Levenback, C, Chantarawiroj, P, Gonzalez de Leon, C, Kim, E E, Madden, T, Wallin, B, Hord, M, Verschraegen, C, Raber, M, Kavanagh, J J

“…To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to…”
Get more information

Pegylated liposomal doxorubicin with bevacizumab in the treatment of platinum-resistant ovarian cancer: Toxicity profile results by Czok, S, Jewell, A, Shawki, S, Boyd, L, Smith, H, Blank, S, Muller, C, Verschraegen, C, Muggia, F

Get full text

Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets by Rasila, K K, Burger, R A, Smith, H, Lee, F C, Verschraegen, C

“…The purpose of this article is to review the current literature pertaining to various angiogenic stimulators and angiogenesis inhibitors in gynecological…”
Get more information

Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors by Hu, W, McCrea, P D, Deavers, M, Kavanagh, J J, Kudelka, A P, Verschraegen, C F

“…Fascin bundles actin microfilaments within dynamic cellular structures such as microspikes, stress fibers and membrane ruffles. Fascin overexpression induces…”
Get full text